Illinois Municipal Retirement Fund Trims Position in Cencora, Inc. $COR

Illinois Municipal Retirement Fund decreased its holdings in Cencora, Inc. (NYSE:COR) by 35.7% during the second quarter, HoldingsChannel.com reports. The institutional investor owned 10,373 shares of the company’s stock after selling 5,763 shares during the quarter. Illinois Municipal Retirement Fund’s holdings in Cencora were worth $3,110,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds have also recently modified their holdings of the business. Invesco Ltd. grew its holdings in Cencora by 42.1% during the first quarter. Invesco Ltd. now owns 4,607,964 shares of the company’s stock valued at $1,281,429,000 after purchasing an additional 1,364,433 shares during the period. T. Rowe Price Investment Management Inc. raised its position in shares of Cencora by 4,459.6% during the 1st quarter. T. Rowe Price Investment Management Inc. now owns 997,233 shares of the company’s stock valued at $277,321,000 after purchasing an additional 975,362 shares during the period. Price T Rowe Associates Inc. MD increased its stake in Cencora by 8.9% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 9,647,310 shares of the company’s stock worth $2,682,821,000 after buying an additional 787,858 shares in the last quarter. Nuveen LLC purchased a new position in shares of Cencora in the first quarter valued at about $181,284,000. Finally, Caisse DE Depot ET Placement DU Quebec raised its stake in Cencora by 144.4% during the 1st quarter. Caisse DE Depot ET Placement DU Quebec now owns 743,072 shares of the company’s stock valued at $206,641,000 after purchasing an additional 439,008 shares during the period. Institutional investors own 97.52% of the company’s stock.

Insider Buying and Selling

In related news, CEO Robert P. Mauch sold 5,097 shares of the stock in a transaction that occurred on Monday, October 20th. The stock was sold at an average price of $326.80, for a total value of $1,665,699.60. Following the transaction, the chief executive officer owned 37,940 shares of the company’s stock, valued at $12,398,792. This represents a 11.84% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, Chairman Steven H. Collis sold 31,350 shares of the firm’s stock in a transaction on Tuesday, September 16th. The stock was sold at an average price of $289.86, for a total value of $9,087,111.00. Following the transaction, the chairman owned 305,913 shares in the company, valued at $88,671,942.18. The trade was a 9.30% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last ninety days, insiders have sold 41,544 shares of company stock worth $12,230,941. Corporate insiders own 10.80% of the company’s stock.

Cencora Price Performance

Shares of COR stock opened at $363.75 on Thursday. The company has a debt-to-equity ratio of 3.64, a quick ratio of 0.53 and a current ratio of 0.90. The stock has a 50 day moving average price of $318.52 and a 200 day moving average price of $301.12. Cencora, Inc. has a 52-week low of $223.92 and a 52-week high of $366.17. The firm has a market capitalization of $70.52 billion, a P/E ratio of 37.42, a P/E/G ratio of 1.56 and a beta of 0.63.

Cencora (NYSE:COR) last issued its earnings results on Wednesday, November 5th. The company reported $3.84 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $3.79 by $0.05. The firm had revenue of $83.73 billion during the quarter, compared to analyst estimates of $83.36 billion. Cencora had a net margin of 0.60% and a return on equity of 267.36%. The business’s revenue was up 5.9% on a year-over-year basis. During the same period in the previous year, the firm earned $3.34 earnings per share. Cencora has set its FY 2026 guidance at 17.450-17.75 EPS. As a group, sell-side analysts predict that Cencora, Inc. will post 15.37 earnings per share for the current year.

Cencora Increases Dividend

The business also recently announced a quarterly dividend, which will be paid on Monday, December 1st. Shareholders of record on Friday, November 14th will be paid a $0.60 dividend. The ex-dividend date is Friday, November 14th. This represents a $2.40 dividend on an annualized basis and a yield of 0.7%. This is an increase from Cencora’s previous quarterly dividend of $0.55. Cencora’s payout ratio is currently 30.19%.

Analyst Upgrades and Downgrades

Several equities research analysts have recently issued reports on COR shares. Morgan Stanley set a $330.00 price objective on shares of Cencora and gave the company an “equal weight” rating in a research report on Wednesday, July 16th. Weiss Ratings reaffirmed a “buy (b-)” rating on shares of Cencora in a research note on Thursday, October 30th. JPMorgan Chase & Co. upped their price target on shares of Cencora from $344.00 to $417.00 and gave the company an “overweight” rating in a research note on Tuesday. Mizuho increased their price target on shares of Cencora from $340.00 to $380.00 and gave the company an “outperform” rating in a report on Thursday, November 6th. Finally, TD Cowen boosted their target price on Cencora from $350.00 to $400.00 and gave the company a “buy” rating in a research report on Monday. Nine analysts have rated the stock with a Buy rating and three have given a Hold rating to the company’s stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $371.09.

About Cencora

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.